Foghorn Therapeutics Inc (FHTX) Actualités

Form 8-K - Current report

Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook

First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial...

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a...

Form 8-K - Current report

Form EFFECT - Notice of Effectiveness

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form S-3 - Registration statement under Securities Act of 1933

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025

First-in-class oral selective SMARCA2 (BRM) inhibitor, FHD-909 (LY4050784), advancing in Phase 1 trial for...